Kinexcs

Market position

Kinexcs positions itself in the digital MSK rehabilitation market, combining wearables and AI with clinician workflows. The provided sources contain no third-party market share data, rankings or competitor comparisons.

Company materials point to patented and proprietary sensing technologies underlying KIMIA Recover, remote gait assessment that removes the need for a specialised gait lab, gamified exercise programs, and a claimed FDA approval for its flagship product. These claims come from the company's own website and are not independently corroborated in the sources provided.

Technology

The KIMIA system combines a wearable knee sensor built on patented and proprietary sensing technologies with software for assessment and monitoring. The sensor tracks knee and hip range of motion and mobility; assessment technology remotely gathers gait parameters. Data flows to a patient mobile app and a clinician dashboard supporting feedback and real-time guidance during therapy. Job listings describe a backend architecture on AWS, RESTful APIs, SQL and NoSQL databases, mobile app development in Flutter/Dart, and NodeJS/ExpressJS and Flask experience as preferred, with documentation maintained for medical-device compliance and quality management.

Go-to-market

The company reaches patients through orthopedic surgeons and physical therapy centres, offering at-home assessment and app-based therapy with clinician oversight, and invites direct contact through its website. It has also used accelerators, competitions and grant programs (Cedars-Sinai Accelerator, SLINGSHOT Singapore, NHIC I2I grant, Johnson & Johnson QuickFire Challenge) for visibility and funding.

Patients undergoing orthopedic surgery (notably total knee replacement and ACL cases), people recovering from injuries, and individuals with general musculoskeletal aches, stiffness or joint pain; also orthopedic surgeons, physical therapists and therapy centres who monitor patients via a clinician dashboard, plus health and fitness seekers addressed by KIMIA Deskercise.

Geography

Kinexcs lists a Singapore headquarters at Blk 75 Ayer Rajah Crescent #02-08, Singapore 139953, with an earlier site page also listing 20A Tanjong Pagar Road. Following its 2023 funding, the company identified target markets in Singapore, Hong Kong, Malaysia, Thailand, India, the United States, Canada, Germany, the Netherlands, Switzerland and the United Kingdom.

History

Company sources describe a 2023 Pre-Series A round of S$4.1 million led by Pureland Ventures and Enterprise Singapore, alongside claimed milestones including FDA approval for its flagship product, quadrupled revenue versus the prior financial year, and recognitions such as Forbes 100 in Asia, SLINGSHOT Singapore 2nd runner-up, an NHIC I2I grant selection and a Johnson & Johnson QuickFire Challenge Award. In 2024 the company announced selection into the Cedars-Sinai Accelerator (Class 10) and published a post on clinical validation of KIMIA Recover's gamified total knee replacement rehabilitation program. The company said it was preparing for a Series A round. Website materials also show an earlier office address at 20A Tanjong Pagar Road and a current address at Blk 75 Ayer Rajah Crescent, Singapore.

Risks & controversies

Key claims — FDA approval, quadrupled revenue, and award recognitions — originate solely from the company's own blog post and are not independently verified in the material provided. Internal records list a Bangalore, India headquarters while all public company sources list a Singapore address, an unresolved discrepancy. Revenue targets are forward-looking statements.